Adherence is a strong predictor of the virological response (1-3) and the survival (4, 5) 63 of HIV-infected patients. Therefore, improving adherence has been an area of intense research 64 among patients receiving antiretroviral therapy (ART). Efforts have focused on interventions 65 aimed at changing patient behavior (6) and on improving treatment characteristics, leading to 66 the simplification of treatment (7). Adherence to ART has generally been reported as the 67 average number of doses taken divided by the prescribed doses during a defined period of 68 observation (8). The two major limits of this analytical approach are (i) that it does not 69 account for the dynamics of adherence (9) and (ii) that it does not account for the drug intake 70 pattern (10). Depending on the ART class in terms of the pharmacokinetic profile, antiviral 71 potency (11-13) and phase of treatment (14), different patterns of adherence have been 72 associated with different virological outcomes. For example, the average adherence to boosted 73 protease inhibitors (PI) was found to be closely associated with the virological outcome (12, 74 15) . Whether strict inter-dose timing is required for virological suppression is not known. 75
Moreover, the ability to consider measurements of adherence to one drug as a surrogate for 76 adherence to all drugs is speculative. The simultaneous intake of several individual 77 components of combination ART is also required for optimal efficacy. Selective drug intake 78 can lead to periods of single or dual agent exposure. There has been inconsistent data 79 regarding the frequency of differential adherence (16, 17) , which has been shown to be 80 associated with virological failure and drug resistance (18) . 81
Another challenge is the method used to assess adherence to prescribed ART (19, 20) . 82
Although there is no gold standard, electronic monitoring appears to be the most reliable 83 method to record dose timing in the research setting (19, 20) . 84
The objectives of this work were to assess the concordance between different 85 adherence measurement methods and to describe the dynamics of adherence to a newly 86 initiated ART regimen. Medication Event Monitoring System caps were used to assess the 87 simultaneity of drug taking. We identified adherence factors that correlated with virological 88 suppression during the first 6 months of an antiretroviral regimen consisting of ritonavir-89 boosted atazanavir (ATV/RTV) combined with tenofovir/emtricitabine (Truvada, TVD) in 90 antiretroviral-naive participants enrolled in the ANRS 134-COPHAR 3 trial. 91 92 93 94
Methods 96

Study design and population 97
The ANRS 134-COPHAR 3 trial was a multicenter prospective study conducted on HIV-1-98 infected treatment-naive patients starting a PI-containing ART regimen consisting of 300 mg 99 of atazanavir (2 capsules of 150 mg) boosted with 100 mg ritonavir (1 soft capsule) and a 100 fixed dose combination of two co-formulated nucleoside analogs: tenofovir disoproxil 101 fumarate (300 mg) and emtricitabine (200 mg). Thirty-five patients were included and were 102 followed for 24 weeks. The trial enrolled HIV-1-infected subjects from the outpatient clinics 103 of 14 French university and general hospitals and was completed between February and 104 November 2008. All patients" viruses were demonstrated to be sensitive to each component of 105 the therapy using a genotypic resistance assay prior to inclusion of the patients in the study. 106
The study was performed according to 
Measurements of patient adherence to the ART regimen 120
We used three methods to assess adherence. First, a pharmacist performed a monthly 121 announced pill count for each ART component. Second, self-reported adherence was 122 measured using the ANRS adherence questionnaire (9) at W4, W16 and W24. Briefly, the 123 questionnaire asked subjects to report the number of missed doses during a 4-day period, the 124 last week end and a 4-week period to detect subjects with < 95% adherence. Third, the 125 adherence was prospectively monitored using three Medication Event Monitoring System 126 caps (MEMS®; AARDEX Group, Switzerland), one for each bottle containing atazanavir 127 capsules, ritonavir soft-capsules or tenofovir/emtricitabine fixed dose regimen tablets. The 128 patients and physicians were not aware of the dosing history data compiled using the MEMScaps during the study. Each bottle containing antiretroviral drugs was filled by the pharmacist 130 who delivered the drugs monthly to the pharmacy hospital during refill. The MEMS caps 131 monitored the exact time and date of the opening of each pill bottle. We summarized the 132 adherence as (1) the taking compliance (corresponding to the number of openings divided by 133 the number of prescribed doses), (2) correct dosing (corresponding to the number of days with 134 openings performed as prescribed divided by the number of monitored days) and (3) the 135 timing compliance (corresponding to the number of openings +/-3 hours from the dosing 136 prescription divided by the number of prescribed doses). The simultaneity of the drug intake 137 was evaluated based on the delays between MEMS cap openings. Because we found high 138 levels of simultaneity, we averaged the adherence of the 3 MEMS caps for the subsequent 139
analyses. Finally, we assessed the self-reported impact of MEMS use on convenience and 140 adherence at the end of the trial. 141
142
Virological outcomes 143
The cross-sectional virological success was defined at three different time points according to 144 the French guidelines 145 (http://www.sante.gouv.fr/IMG/pdf/Rapport_2010_sur_la_prise_en_charge_medicale_des_pe 146 rsonnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni.pdf) as follows: an 147 HIV-RNA reduction of > 2 log 10 at W4, a viral load < 400 cp/mL at W12 and a viral load < 148 40 cp/mL at W24. 149
To assess the relationship between MEMS-defined adherence and virological suppression, we 150 defined dynamic virological suppression (DVS), which takes into account the dynamics of 151 both adherence and viral decline following ART initiation. DVS was evaluated at the end of 152 each of five time periods (W0-W4, W4-W8, W8-W12, W12-W16 and W16-W24) and was 153 defined as an HIV-RNA level reduction of > 1 log 10 per 4-week period (3) or a level < 40 154 copies/mL. The ends of the periods corresponded to the times at which HIV-RNA 155 measurements were performed as part of the ANRS 134-COPHAR 3 trial. 156
157
Statistical analysis 158
The sample size was defined for the pharmacokinetic analysis of atazanavir with ritonavir 159 (21). The categorical variables were summarized using percentages, and continuous variables, 160 such as adherence, were summarized using medians and ranges. The agreement between the 161 methods for discriminating adherence > 95% during similar periods was calculated using 162
Cohen"s Kappa coefficient. The longitudinal data with repeated measurements were analyzedusing generalized linear mixed models (22, 23) . For the continuous outcomes, such as 164 adherence, we used the MIXED procedure in SAS with the same 5 periods defined for DVS. 165
To analyze DVS, which is a discrete binary variable, we used the GLIMMIX procedure in 166 SAS. The abilities of several separate models to predict DVS using the MEMS-defined 167 adherence measurements (percentages of doses taken, days with correct dosing and doses 168 taken on time) were assessed by the area under the Receiver Operating Characteristic (ROC) 169
curve. In addition, a cut-off for adherence that can predict DVS was explored by computing 170 the sensitivity, specificity and Youden J index in R (package "pROC": http://cran.r-171 project.org/web/packages/pROC/pROC.pdf). The analyses were conducted with SAS 172 software V 9.2 (SAS institute, Cary, NC), and a p-value < 0.05 was considered statistically 173 significant. 174 175 176
Results
177
Baseline characteristics, efficacy and tolerance 178
Thirty-five subjects were included in the study. Their baseline characteristics are shown in 179 Self-reported adherence questionnaires generally tend to overestimate adherence (24). In our 254 study, more patients were classified as <95% adherent with questionnaires compared with 255 MEMS or pill count. This might be due to the stringent algorithm we used to classify self-256 reported adherence in the questionnaire and the difference between perceived adherence and 257 objective adherence. Bilirubin level, which is more objective,, has been linked to adherence to 258 atazanavir (25, 26). Of note, our dataset served for external validation of the use of bilirubin 259 level to detect sub-optimal atazanavir exposure, as reported elsewhere (27). Nevertheless, the 260 bilirubin normogram and therapeutic drug monitoring of atazanavir concentrations had lower 261 predictive power to detect past non-adherence episodes. In addition, only MEMS can provide 262 a reliable history of timing compliance. Consistent with previous studies, the MEMS data 263 exhibited strong agreement with the pharmacy adherence data (28). Gross et al. reported a 264 lower overall MEMS-defined taking compliance of 84% during the first 4-month period ofantiretroviral therapy with nelfinavir (3). The differences between our study and the study of 266
Gross et al. could be explained by differences in a better tolerance profile or simpler dosing 267 for the ATV/RTV plus TVD QD regimen. Other alternative explanations for high adherence 268 levels are selection bias and the Hawthorne effect. The volunteers, who agreed to use the 269 MEMS caps and to undergo more frequent blood sampling to participate in the clinical trial, 270 may be more likely to adhere. In turn, such intensive monitoring may also support and sustain 271 high adherence levels, as shown in a prior intervention study using MEMS (29) and in the 272 qualitative evaluation of the MEMS in our study. The virological success rate reported in this 273 trial (91% of HIV-RNA levels <50 cp/mL at W24) outperformed the results of the CASTLE 274 study (70% of HIV-RNA levels <50 cp/mL at W24), one of the largest trial to evaluate the 275 use of ATV/RTV and TVD by treatment-naive HIV-infected patients (30). Of note, contrary 276 to the CASTLE study, all our patients were assessed for treatment drug resistance, and we 277 planned to exclude patients with resistance mutations to any drug in the combined regimen. 278
Although it has been suggested that newer potent antiretroviral combinations are effective at 279 moderate levels of adherence (17, 31, 32), we found herein a significant association between 280 average adherence and dynamic virological suppression in the context of high levels of 281 adherence. The dose timing has been previously reported as an important factor to achieve 282 virological success with antiretroviral therapy (33, 34). The added value of incorporating dose 283 timing errors has received less scrutiny. In a previous study (21), the use of MEMS-defined 284 dosing data halved the unexplained variability in ATV clearance. Of note, the use of timing 285 compliance improved our ability to predict insufficient DVS relative to the use of the 286 percentages of doses taken and days with correct dosing ( Figure 2B) , with an optimized 287 predictive value at the timing compliance cut-off of 78%. This result might be specific to the 288 short half-life of ATV/RTV (mean, 7 to 10 hours), which requires regular inter-dose intervals 289 for the drug concentration to remain within the therapeutic range. In addition, timing 290 compliance may be more relevant for atazanavir and tenofovir due to the food effect, which 291 enhances bioavailability and reduces pharmacokinetic variability (35). We hypothesized that 292 the variability in the ATV pharmacokinetics related to timing compliance (21) also influenced 293 DVS among treatment-naive HIV-infected subjects starting antiretroviral therapy, 294 strengthening the link between pharmacokinetics and pharmacodynamics. 295
The level of simultaneity in taking drugs was rather good, in accordance with the results of a 296 previous study (16) but in contrast to the results of Shuter et al., who found 47% of the 297 patients staggered at least once the doses of ritonavir (36).
Adherence declined over time. Gross et al. (3) reported that there is a 1-month "honeymoon" 299 period after treatment initiation before the adherence rate begins to decline. In our study, the 300 dose timing and correct dosing were more affected by pill burden fatigue than the taking 301 compliance was in the context of a QD 4-pill regimen. This result supports the 302 recommendation to that QD ATV/RTV and TVD be taken at a regular time every day during 303 the early stage of treatment. Whether this statement remains valid for the maintenance phase, 304 once virological suppression has been achieved, is unknown, however. 305
None of the adherence measures was significantly associated with the milestone of cross-306 sectional virological success at W4, W12 and W24 as defined in international guidelines. The 307 statistical power for this analysis was limited, while our 35 patients showed a high adherence 308 levels. Interestingly and counter-intuitively, the percentage of virological success increased 309 between W4 and W12, while MEMS-defined adherence decreased after the first month. 310
311
We are aware of the limitations in this study. First, the sample size was rather small as it was 312 defined for the pharmacokinetics analysis of atazanavir with ritonavir (21). We took 313 advantage of the dynamics of both virological suppression and adherence to study several 314 periods per subject. We were able to increase the power of the longitudinal analysis of the 315 DVS compared to the cross-sectional analysis of virological success. Nevertheless, we could 316 not adjust for confounding variables when predicting the virological outcome. Second, the 317 follow-up was limited to 6 months, even though the use of antiretroviral therapy is life long. 318
However, the effect of non-adherence seems to wane over time, and the first 6 months are 319 therefore critical. Third, our study population had a relatively good immuno-virological status 320 at the start of the study, and both the potency and the pharmacological characteristics of 321 recent antiretroviral drugs have improved in the last decade. These improvements have led to 322 the development of simpler regimens that are easier to adhere to and have led to more robust 323 virological effects. Patients are also being treated sooner than previously, and all these factors 324 result in improved treatment efficacy. Fourth, because our study population had a high overall 325 adherence level, gaps in medications were infrequent. In addition, treatment gaps and the 326 coefficient of variation in dose timing are strongly correlated (37). Therefore, we were unable 327 to incorporate such gaps as a factor. Finally, our results cannot be extrapolated to treatment-328 
